Y-box binding protein-1 is a novel molecular target for tumor vessels.
Y-box binding protein-1 (YB-1) is a member of the cold shock protein family and functions in transcription and translation. Many reports indicate that YB-1 is highly expressed in tumor cells and is a marker for tumor aggressiveness and clinical prognosis. Here, we show clear evidence that YB-1 is expressed in the angiogenic endothelial cells of various tumors, such as glioblastoma, esophageal cancer, gastric cancer, colon cancer, and lung cancer, as well as in tumor cells. YB-1 was highly expressed in glomeruloid microvascular endothelial cells of brain tumors and microvessels in the desmoplastic region around multiple solid tumors. On the other hand, no or low YB-1 expression was observed in normal angiogenic endothelial cells from fetal kidney, newborn lung, and placenta. The endothelial cells in inflammatory regions of granulomas were also weakly labeled. Knockdown of YB-1 expression by small-interfering RNA induced G1 cell cycle arrest and inhibited the growth of human umbilical vein endothelial cells stimulated by growth factors. Taken together, YB-1 plays an important role in the growth of not only tumor cells but also tumor-associated endothelial cells, suggesting that YB-1 is a promising target for cancer therapy.
Takahashi
Mayu
M
Department of Molecular Biology, University of Occupational and Environmental Health, Kitakyushu, Japan.
Shimajiri
Shohei
S
Izumi
Hiroto
H
Hirano
Gen
G
Kashiwagi
Eiji
E
Yasuniwa
Yoshihiro
Y
Wu
Ying
Y
Han
Bin
B
Akiyama
Masaki
M
Nishizawa
Shigeru
S
Sasaguri
Yasuyuki
Y
Kohno
Kimitoshi
K
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000098:blood supply / Q000737:chemistry; D002478:Cells, Cultured; D004268:DNA-Binding Proteins / Q000032:analysis / Q000037:antagonists & inhibitors / Q000502:physiology*; D042783:Endothelial Cells / Q000502:physiology; D005909:Glioblastoma / Q000098:blood supply / Q000737:chemistry; D006801:Humans; D009369:Neoplasms / Q000098:blood supply*; D009389:Neovascularization, Pathologic; D009687:Nuclear Proteins / Q000032:analysis / Q000037:antagonists & inhibitors / Q000502:physiology*; D051840:Y-Box-Binding Protein 1
D020533:Angiogenesis Inhibitors; D004268:DNA-Binding Proteins; D009687:Nuclear Proteins; D051840:Y-Box-Binding Protein 1; C070856:YBX1 protein, human
Cancer Res. 2005 May 15;65(10):4078-87
15899797
Cancer Sci. 2003 Jan;94(1):9-14
12708467
Cancer Res. 2001 Sep 15;61(18):6649-55
11559528
Nucleic Acids Res. 2004 Jan 29;32(2):611-22
14752049
J Clin Oncol. 2007 Apr 1;25(10):1196-208
17401009
Cancer Res. 2006 May 1;66(9):4872-9
16651443
Am J Pathol. 2001 Mar;158(3):1145-60
11238063
Brain. 2007 Dec;130(Pt 12):3336-41
17998256
N Engl J Med. 1971 Nov 18;285(21):1182-6
4938153
Mol Cancer Ther. 2008 Dec;7(12):3670-84
19074844
J Cell Biochem. 2007 Jul 1;101(4):887-907
17266048
Science. 2000 Aug 18;289(5482):1197-202
10947988
Cancer Res. 1996 Sep 15;56(18):4224-8
8797596
Nature. 2001 May 17;411(6835):375-9
11357145
Nat Rev Cancer. 2008 Aug;8(8):579-91
18596824
Eur J Cancer. 2010 Mar;46(5):954-65
20079629
Mol Cancer Ther. 2004 Nov;3(11):1485-92
15542787
Cancer Res. 2008 Jan 1;68(1):98-105
18172301
Science. 2009 Jun 12;324(5933):1457-61
19460966
Cancer Res. 2004 Oct 1;64(19):6892-9
15466178
Oncogene. 2007 Jul 19;26(33):4749-60
17297441
Nat Med. 2004 Aug;10(8):789-99
15286780
Nature. 2001 May 17;411(6835):355-65
11357143
Mol Cancer Ther. 2009 Dec;8(12):3276-84
19996271
J Biol Chem. 2006 Dec 29;281(52):40440-9
17082189
J Pathol. 2003 Feb;199(2):251-8
12533839
Eur J Cancer. 2005 Nov;41(16):2577-86
16209921
Int J Cancer. 2009 Sep 1;125(5):1222-30
19431144
Curr Med Chem Anticancer Agents. 2005 Jan;5(1):15-27
15720258
Nat Rev Drug Discov. 2007 Apr;6(4):273-86
17396134
Annu Rev Med. 2006;57:1-18
16409133
Bioessays. 2003 Jul;25(7):691-8
12815724
J Neurooncol. 2009 Oct;95(1):13-22
19381445